Your browser doesn't support javascript.
loading
A Pan-Cancer Patient-Derived Xenograft Histology Image Repository with Genomic and Pathologic Annotations Enables Deep Learning Analysis.
White, Brian S; Woo, Xing Yi; Koc, Soner; Sheridan, Todd; Neuhauser, Steven B; Wang, Shidan; Evrard, Yvonne A; Chen, Li; Foroughi Pour, Ali; Landua, John D; Mashl, R Jay; Davies, Sherri R; Fang, Bingliang; Rosa, Maria Gabriela; Evans, Kurt W; Bailey, Matthew H; Chen, Yeqing; Xiao, Min; Rubinstein, Jill C; Sanderson, Brian J; Lloyd, Michael W; Domanskyi, Sergii; Dobrolecki, Lacey E; Fujita, Maihi; Fujimoto, Junya; Xiao, Guanghua; Fields, Ryan C; Mudd, Jacqueline L; Xu, Xiaowei; Hollingshead, Melinda G; Jiwani, Shahanawaz; Acevedo, Saul; Davis-Dusenbery, Brandi N; Robinson, Peter N; Moscow, Jeffrey A; Doroshow, James H; Mitsiades, Nicholas; Kaochar, Salma; Pan, Chong-Xian; Carvajal-Carmona, Luis G; Welm, Alana L; Welm, Bryan E; Govindan, Ramaswamy; Li, Shunqiang; Davies, Michael A; Roth, Jack A; Meric-Bernstam, Funda; Xie, Yang; Herlyn, Meenhard; Ding, Li.
Afiliação
  • White BS; The Jackson Laboratory for Genomic Medicine, Farmington, Connecticut.
  • Woo XY; The Jackson Laboratory for Genomic Medicine, Farmington, Connecticut.
  • Koc S; Bioinformatics Institute (BII), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
  • Sheridan T; Velsera, Charlestown, Massachusetts.
  • Neuhauser SB; The Jackson Laboratory for Genomic Medicine, Farmington, Connecticut.
  • Wang S; The Jackson Laboratory, Bar Harbor, Maine.
  • Evrard YA; University of Texas Southwestern Medical Center, Dallas, Texas.
  • Chen L; Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland.
  • Foroughi Pour A; Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland.
  • Landua JD; The Jackson Laboratory for Genomic Medicine, Farmington, Connecticut.
  • Mashl RJ; Baylor College of Medicine, Houston, Texas.
  • Davies SR; Washington University School of Medicine, St. Louis, Missouri.
  • Fang B; Washington University School of Medicine, St. Louis, Missouri.
  • Rosa MG; University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Evans KW; University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Bailey MH; University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Chen Y; Simmons Center for Cancer Research, Brigham Young University, Provo, Utah.
  • Xiao M; The Wistar Institute, Philadelphia, Pennsylvania.
  • Rubinstein JC; The Wistar Institute, Philadelphia, Pennsylvania.
  • Sanderson BJ; The Jackson Laboratory for Genomic Medicine, Farmington, Connecticut.
  • Lloyd MW; The Jackson Laboratory for Genomic Medicine, Farmington, Connecticut.
  • Domanskyi S; The Jackson Laboratory, Bar Harbor, Maine.
  • Dobrolecki LE; The Jackson Laboratory for Genomic Medicine, Farmington, Connecticut.
  • Fujita M; Baylor College of Medicine, Houston, Texas.
  • Fujimoto J; Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
  • Xiao G; University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Fields RC; University of Texas Southwestern Medical Center, Dallas, Texas.
  • Mudd JL; Washington University School of Medicine, St. Louis, Missouri.
  • Xu X; Washington University School of Medicine, St. Louis, Missouri.
  • Hollingshead MG; The Wistar Institute, Philadelphia, Pennsylvania.
  • Jiwani S; National Cancer Institute, Bethesda, Maryland.
  • Acevedo S; Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland.
  • Robinson PN; Velsera, Charlestown, Massachusetts.
  • Moscow JA; The Jackson Laboratory for Genomic Medicine, Farmington, Connecticut.
  • Doroshow JH; National Cancer Institute, Bethesda, Maryland.
  • Mitsiades N; National Cancer Institute, Bethesda, Maryland.
  • Kaochar S; Baylor College of Medicine, Houston, Texas.
  • Pan CX; Baylor College of Medicine, Houston, Texas.
  • Carvajal-Carmona LG; University of California, Davis, Davis, California.
  • Welm AL; University of California, Davis, Davis, California.
  • Welm BE; Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
  • Govindan R; Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
  • Li S; Washington University School of Medicine, St. Louis, Missouri.
  • Davies MA; Washington University School of Medicine, St. Louis, Missouri.
  • Roth JA; University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Meric-Bernstam F; University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Xie Y; University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Herlyn M; University of Texas Southwestern Medical Center, Dallas, Texas.
  • Ding L; The Wistar Institute, Philadelphia, Pennsylvania.
Cancer Res ; 84(13): 2060-2072, 2024 Jul 02.
Article em En | MEDLINE | ID: mdl-39082680
ABSTRACT
Patient-derived xenografts (PDX) model human intra- and intertumoral heterogeneity in the context of the intact tissue of immunocompromised mice. Histologic imaging via hematoxylin and eosin (H&E) staining is routinely performed on PDX samples, which could be harnessed for computational analysis. Prior studies of large clinical H&E image repositories have shown that deep learning analysis can identify intercellular and morphologic signals correlated with disease phenotype and therapeutic response. In this study, we developed an extensive, pan-cancer repository of >1,000 PDX and paired parental tumor H&E images. These images, curated from the PDX Development and Trial Centers Research Network Consortium, had a range of associated genomic and transcriptomic data, clinical metadata, pathologic assessments of cell composition, and, in several cases, detailed pathologic annotations of neoplastic, stromal, and necrotic regions. The amenability of these images to deep learning was highlighted through three applications (i) development of a classifier for neoplastic, stromal, and necrotic regions; (ii) development of a predictor of xenograft-transplant lymphoproliferative disorder; and (iii) application of a published predictor of microsatellite instability. Together, this PDX Development and Trial Centers Research Network image repository provides a valuable resource for controlled digital pathology analysis, both for the evaluation of technical issues and for the development of computational image-based methods that make clinical predictions based on PDX treatment studies.

Significance:

A pan-cancer repository of >1,000 patient-derived xenograft hematoxylin and eosin-stained images will facilitate cancer biology investigations through histopathologic analysis and contributes important model system data that expand existing human histology repositories.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Aprendizado Profundo / Neoplasias Limite: Animals / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Aprendizado Profundo / Neoplasias Limite: Animals / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article